A recent report from The Telegraph reveals that pharmaceutical giant AstraZeneca has admitted in court documents that its Covid vaccine, Covishield, can lead to rare side effects. These include a condition known as Thrombosis with Thrombocytopenia Syndrome (TTS), which involves blood clots and low platelet counts. Covishield, developed by AstraZeneca and Oxford University and produced by the Serum Institute of India, has come under scrutiny as individuals have reported severe adverse reactions, including permanent brain injury and even death.
In recent legal proceedings, AstraZeneca acknowledged that Covishield can, in very rare cases, trigger TTS. Despite contesting some claims, the company admitted the potential link between the vaccine and these serious health issues. However, AstraZeneca maintains that the causal mechanism remains unclear and asserts that TTS can occur independently of the vaccine.
The admission comes amidst a class action lawsuit in the UK, where victims and their families are seeking substantial damages from AstraZeneca. The lawsuit highlights alleged deaths and severe injuries associated with the Covishield vaccine. AstraZeneca’s acknowledgment in court documents may signal potential payouts to affected individuals and their loved ones.
Interestingly, this recent admission contradicts AstraZeneca’s previous stance in 2023, where the company denied a direct link between the vaccine and TTS. Despite acknowledging rare side effects, AstraZeneca has refuted claims that the vaccine is inherently defective or that its efficacy is exaggerated.
Since the early stages of the vaccine rollout in 2021, scientists identified a connection between Covishield and a condition called vaccine-induced immune thrombocytopenia and thrombosis (VITT), which some lawyers argue is a subset of TTS. However, AstraZeneca’s acknowledgment of TTS does not explicitly address this claim.
The evolving legal battle and AstraZeneca’s admission underscore the complexities surrounding vaccine safety and highlight the importance of ongoing research and transparency in addressing public health concerns.
